Back to dashboard
Episode 320
DIP Episode 320 - USMLE Step 2CK Rapid Review Series 59 (and 20hr 2CK/3 course reminder 6/18-19)
MixedMedium4 - HighHas Q&A
Step 2Step 3MedicineUSMLEStep 2Step 3
Topic
Hepatobiliary disease (PBC vs PSC); Multiple Myeloma; Volume depletion physiology (RAAS axis); Cardiac shunts and polycythemia.
Key Takeaway
Understanding the specific pathophysiology of hepatobiliary diseases (e.g., PBC affecting intrahepatic ducts, PSC affecting both) and systemic conditions like multiple myeloma or hypovolemic shock is critical for interpreting complex board-style clinical vignettes.
Runtime: 24.6 min
Published: 2021-06-14
Completed audio: Yes
Completed notes: Yes
Anki made: Yes
Section: RAPID REVIEW SERIES
Episode Notes
Source / episode info
- Episode: 320
- Title: Divine Intervention Episode 320 – USMLE Step 2 CK Rapid Review Series 59 (and 20hr 2 CK/3 course reminder 6/18-19).
- Published: 2021-06-14
- Source: Episode page
One-liner
This episode provides a rapid review of high-yield topics including the differentiation between Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), the systemic manifestations and treatment mechanism for Multiple Myeloma, and the complex physiology governing volume depletion and cardiac shunts.
High-yield summary
- PBC vs PSC: PBC is typically associated with anti-mitochondrial antibodies (AMA) and affects only the intra-hepatic bile ducts; PSC involves both intra and extra-hepatic ducts.
- Multiple Myeloma (MM): The classic mnemonic for MM findings is CRAB: Calcium elevation (hypercalcemia), Renal failure (due to light chain deposition/amyloidosis), Anemia, and Bone pain (osteolytic lesions).
- MM Treatment: Bortezomib, a proteasome inhibitor, is the drug of choice because it prevents the degradation of pro-apoptotic proteins, allowing myeloma cells to undergo apoptosis.
- Hypovolemia Physiology: Volume depletion activates the RAAS system, leading to increased aldosterone secretion. This causes sodium reabsorption and potassium wasting (hypokalemia) and proton excretion (metabolic alkalosis).
- BUN/Cr Ratio: In hypovolemic states, the BUN rises faster than creatinine because of enhanced tubular handling driven by ADH/aldosterone effects on urea/sodium balance.
- Cardiac Shunts: A large Patent Ductus Arteriosus (PDA) causes a left-to-right shunt; chronic hypoxia (e.g., from severe pulmonary disease) can reverse this to a right-to-left, cyanotic shunt.
Learning objectives
- Differentiate the pathophysiology and management of PBC versus PSC.
- Recognize the clinical constellation (CRAB) associated with Multiple Myeloma and understand the mechanism of bortezomib.
- Analyze electrolyte disturbances in hypovolemic states, linking them to RAAS activation.
- Interpret findings related to cardiac shunts and chronic hypoxia.
- Apply knowledge of biliary drainage procedures for malignant obstruction.
Board exam buzzwords
| Condition | Key Finding | Association | Board Exam Tip |
| Primary Biliary Cholangitis (PBC) | Elevated ALP, AMA positive | Intrahepatic bile ducts; associated with pruritus | Remember PBC is intra-hepatic only. UDCA is the primary treatment. |
| Multiple Myeloma (MM) | Hypercalcemia, Bone pain, Anemia, Renal failure | CRAB criteria; Lytic bone lesions | Bortezomib inhibits the proteasome to induce apoptosis in plasma cells. |
| Hypovolemia/Shock | Hypokalemic metabolic alkalosis | RAAS activation -> Aldosterone release | Always think of K+ wasting and H+ loss when volume is low. |
| Patent Ductus Arteriosus (PDA) | Left-to-right shunt (neonatal) | Pulmonary hypertension leads to reversal (R->L) | The initial L->R flow reverses if the pulmonary pressures become higher than systemic pressures. |
Rapid review table
| Topic | Key Point | Context | Exam Relevance |
| PBC vs PSC | PBC: AMA+, intrahepatic; PSC: UC association, extra/intra-hepatic. | Jaundice, elevated ALP. | UDCA treats PBC but not PSC. ERCP is needed for both. |
| Multiple Myeloma | CRAB criteria (Hypercalcemia, Renal failure, Anemia, Bone pain). | Plasma cell dyscrasia; Lytic bone lesions. | Bortezomib targets the proteasome to induce apoptosis. |
| Hypovolemia/Shock | Hypokalemic metabolic alkalosis; Elevated BUN/Cr ratio. | Hemorrhage, severe dehydration. | RAAS activation is key: Aldosterone causes K+ wasting and H+ loss. |
| Cardiac Shunts | PDA (L->R) -> Pulmonary HTN -> R->L shunt. | Chronic cyanotic heart disease. | Polycythemia is a reactive response to chronic hypoxemia, not primary polycythemia vera. |
Board-speak -> diagnosis
| Board-speak / Vignette phrase | Diagnosis / Concept | Why it fits |
| A 42-year-old female with elevated ALP and anti-mitochondrial antibodies (AMA) presents with pruritus. | Primary Biliary Cholangitis (PBC) | AMA is the hallmark serological marker for PBC, which primarily affects intrahepatic ducts. |
| A patient with chronic ulcerative colitis who develops jaundice and bile duct strictures. | Primary Sclerosing Cholangitis (PSC) | PSC involves both intra- and extra-hepatic biliary tree inflammation/stricturing; it has a strong association with UC. |
| An elderly male presenting with bone pain, anemia, hypercalcemia, and renal insufficiency. | Multiple Myeloma (MM) | These four findings constitute the classic CRAB criteria for MM. |
| A patient in hemorrhagic shock develops hypokalemic metabolic alkalosis. | Hypovolemia/RAAS activation | Volume depletion activates RAAS -> Aldosterone release -> K+ wasting and H+ excretion. |
| A neonate with a large PDA presents with signs of pulmonary hypertension over time. | Shunt reversal (L->R to R->L) | Chronic high pressures in the pulmonary circulation can reverse the shunt, leading to cyanosis. |
| An inoperable pancreatic head mass causing jaundice and bile duct obstruction. | Endoscopic stenting/Biliary drainage | Stents are used endoscopically to relieve biliary obstruction caused by local malignancy. |
Differential diagnosis / distinguishing features
Polycythemia Etiologies
| Key Features | Distinguishing Findings | Next Step |
| Reactive/Secondary: Due to chronic hypoxemia (e.g., severe COPD, shunts). | Elevated erythropoietin production; polycythemia count is proportional to hypoxia severity. | Treat the underlying cause of hypoxemia (e.g., supplemental oxygen, cardiac repair). |
| Polycythemia Vera: Primary myeloproliferative neoplasm. | JAK2 mutation positive; elevated platelet and white cell counts often present. | Phlebotomy (blood removal) is the primary treatment to reduce blood viscosity. |
Management pearls
- For suspected PBC, initiate therapy with Ursodeoxycholic acid (UDCA) immediately, as it improves bile flow and liver function.
- When managing MM, remember that the goal of Bortezomib is not just to kill cells, but specifically to inhibit the proteasome, thereby preventing the degradation of pro-apoptotic proteins.
- In hypovolemic shock, fluid resuscitation is paramount; monitor for signs of RAAS activation (hypokalemia, metabolic alkalosis).
- For malignant biliary obstruction (e.g., pancreatic head cancer), endoscopic stenting or percutaneous drainage is required to relieve jaundice and prevent cholangitis.
Don't miss
🚨
The presence of AMA strongly suggests PBC; the absence of AMA does not rule it out, but its presence is highly suggestive.
🚨
MM findings are classically osteolytic lesions on imaging, which contrasts with the typical osteoblastic metastases seen in prostate cancer.
🚨
In hypovolemia, the RAAS axis activation leads to a predictable triad: hypokalemia, metabolic alkalosis, and increased urine sodium reabsorption (low urine Na+).
🚨
The mechanism of polycythemia is often reactive —a compensatory response to chronic tissue hypoxia.
Integration & clinical reasoning
- Hepatobiliary System: Both PBC and PSC involve bile duct inflammation, but the anatomical distribution (intra vs. extrahepatic) dictates the differential diagnosis and management approach.
- Renal/Endocrine Axis: The RAAS system is a critical integrator; hypovolemia triggers it, leading to systemic electrolyte imbalances that must be recognized in any shock state.
- Hematology/Cardiology: Chronic cardiac shunts (PDA) can lead to pulmonary hypertension and subsequent changes in blood gas dynamics, which then drive compensatory hematological responses (polycythemia).
OMM / COMLEX integration
🦴
For COMLEX: know these viscerosomatics / Chapman points, but don't let OMM distract from emergent diagnosis and management.
- Standard emergency management for shock (hypotensive, bleeding) takes absolute priority over OMM/OMT. Fluid resuscitation is the immediate life-saving intervention.
- The understanding of RAAS activation in hypovolemia provides a strong physiological basis for recognizing electrolyte imbalances that can complicate critical care management.
Concept connections / cross-references
- For detailed information on the pathophysiology of liver disease and bile duct anatomy, review [Episode 15].
- The mechanism of aldosterone action and RAAS physiology is covered extensively in [Episode 88].
- Understanding plasma cell dyscrasias and bone metabolism can be reinforced by reviewing general hematology principles in [Episode 201].
High-yield association table
| Condition | Association | Mechanism | Clinical Significance |
| Primary Biliary Cholangitis (PBC) | Anti-mitochondrial antibodies (AMA) | Autoimmune attack on bile duct epithelial cells. | High specificity for PBC; guides diagnosis and treatment with UDCA. |
| Multiple Myeloma (MM) | Proteasome inhibition by Bortezomib | Inhibiting the proteasome prevents the degradation of pro-apoptotic proteins. | Drug of choice therapy, targeting a specific molecular pathway in plasma cells. |
| Hypovolemia/Shock | Aldosterone release via RAAS activation | Increased aldosterone promotes Na+ reabsorption and K+/H+ excretion in the collecting duct. | Leads to hypokalemia and metabolic alkalosis; critical for fluid resuscitation management. |
| Patent Ductus Arteriosus (PDA) | Left-to-right shunt -> Pulmonary HTN -> Right-to-left shunt | Chronic high pulmonary pressures reverse the flow direction. | Requires monitoring of pulmonary vascular resistance to predict shunt reversal and cyanosis. |
Key terms glossary
| Term | Definition | Context | Example |
| AMA (Anti-mitochondrial antibodies) | Antibodies targeting mitochondrial components, specifically in bile duct cells. | Diagnosis of PBC. | Elevated AMA levels strongly suggest Primary Biliary Cholangitis. |
| CRAB Criteria | A mnemonic for the major signs/symptoms of Multiple Myeloma. | Systemic manifestations of plasma cell dyscrasia. | Hypercalcemia, Renal failure, Anemia, Bone pain. |
| Proteasome Inhibitor | Drug class that blocks the proteasomal degradation pathway. | Treatment for MM (e.g., Bortezomib). | By inhibiting it, pro-apoptotic proteins accumulate, causing cancer cell death. |
| Hypovolemia | Reduced circulating blood volume/plasma volume. | Hemorrhage or severe dehydration. | Triggers RAAS activation, leading to compensatory electrolyte changes. |
Study optimization
| Topic | Study Approach | Priority | Resources |
| Hepatobiliary Disease | Compare and contrast PBC vs PSC (location, serology, treatment). | High | Review the bile duct anatomy; memorize AMA association for PBC. |
| Multiple Myeloma | Master the CRAB criteria and the mechanism of Bortezomib. | Very High | Focus on why bortezomib works (proteasome inhibition) rather than just memorizing it is a drug. |
| Fluid/Electrolyte Balance | Trace the physiological cascade: Hypovolemia -> RAAS activation -> Aldosterone effects. | High | Practice linking volume status to specific electrolyte abnormalities (K+, H+). |
Question pattern recognition
- Pattern: Female, middle-aged, elevated ALP, AMA positive -> PBC. This is a classic autoimmune pattern pointing to intrahepatic bile duct injury.
- Pattern: Bone pain + Hypercalcemia + Renal failure + Anemia -> Multiple Myeloma (CRAB). The next step involves checking for plasma cell dyscrasia and considering bortezomib.
- Pattern: Hypovolemic shock/Hemorrhage -> Expect hypokalemic metabolic alkalosis and elevated BUN/Cr ratio due to RAAS activation and ADH effects on tubular handling.
Test yourself
Common mistakes to avoid
🚫
Confusing the anatomical location of inflammation: PBC affects only the intra -hepatic ducts, while PSC involves both intra- and extra-hepatic ducts.
🚫
Misunderstanding the mechanism of MM treatment: Bortezomib inhibits the proteasome to induce apoptosis; it is not a direct cytotoxic agent or calcium blocker.
🚫
Assuming that all polycythemia is primary (Polycythemia Vera); always consider chronic hypoxemia as the cause of reactive polycythemia.
Common traps
⚠️
Trap 1 (PBC/PSC): Do not assume that because both conditions involve bile duct inflammation, they are interchangeable. The anatomical pattern and associated history (AMA for PBC; UC for PSC) are critical differentiators.
⚠️
Trap 2 (MM): Do not confuse the bone findings: MM causes lytic lesions (bone destruction), whereas prostate cancer classically causes osteoblastic/sclerotic metastases.
⚠️
Trap 3 (Hypovolemia): When hypovolemic, remember that RAAS activation leads to loss of K+ and H+, resulting in hypokalemia and metabolic alkalosis—the opposite of what might be expected from simple dehydration.